Zoetis Inc is trading 4% up at $81.98 in a relief rebound following recent pressure tied to litigation headlines and weakness in prior sessions.
- The stock has been hovering near multi-year lows after a sharp May drop linked to allegations over disclosures regarding its Librela osteoarthritis drug.
- Today’s move appears to be a technical recovery from recent selloffs rather than a response to fresh company-specific news, particularly as broader market indices are notably weaker.